A pre-clinical trial study on Afzelin: Anti-human lung cancer, anti-cholinesterase, and anti-glucosidase properties

Introduction Afzelin is a glycosyloxyflavone that is kaempferol attached to an alpha-L-rhamnosyl residue at position 3 via a glycosidic linkage. It has a role as a plant metabolite, an antimicrobial (Antibacterial and antifungal) agent and an anti-inflammatory agent. It is a glycosyloxyflavone, a trihydroxyflavone and a monosaccharide derivative. In this work, we determined the anticholinergic, antiepileptic, antidiabetic, and anti-human lung cancer capacities of afzelin. Material and methods IC50 values were calculated for both acetylcholinesterase, and α-glycosidase as key enzymes effects of afzelin. The cytotoxicity and anticancer potential of human lung over the Afzelin using the common cytotoxicity test i.e., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay in vitro condition. Results IC50 values obtained 365.11 nM for acetyl cholinesterase and 0.94 nM for α-glycosidase were calculated in this study. Indeed, for these enzymes, Ki values were found as 300.65±56.01 nM for acetyl cholinesterase and 1.65±0.11 nM for α-glucosidase. Cell viability of Afzelin was very low against lung poorly differentiated adenocarcinoma (PC-14), lung moderately differentiated adenocarcinoma (LC-2/ad), and lung well-differentiated bronchogenic adenocarcinoma (HLC-1) cell lines without any cytotoxicity on the normal cell line. Conclusions As mentioned, the Afzelin had significant antioxidant and anti-human lung cancer properties. It appears that the anti-human lung carcinoma effect of Afzelin is due to their antioxidant effects.